<span item_type="fundamental" item_id="82ebf5985221d5417807f39bfce4a57c" counter_id="ST/US/WGS" env="prod"></span><span item_type="announcement" item_id="604194328802102529" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 427 M, missing the estimate of USD 427.04 M.</p><p></p><h3>Revenue</h3><p>GeneDx Holdings Corp. expects full year 2025 revenues of approximately $427 million, marking a 41% increase year-over-year. Fourth quarter 2025 revenues are projected at $121 million, a 27% increase year-over-year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/preliminary2025resultspres.htm"></span> Exome and genome revenues for the full year 2025 are expected to be around $360 million, a 54% increase year-over-year, with fourth quarter revenues at $104 million, a 32% increase year-over-year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/preliminary2025resultspres.htm"></span></p><h3>Gross Margin</h3><p>The full year 2025 GAAP and adjusted gross margin are anticipated to be approximately 70% and 71%, respectively. The fourth quarter 2025 GAAP and adjusted gross margin are also expected to be around 70% and 71%, respectively.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/preliminary2025resultspres.htm"></span></p><h3>Cash Flow</h3><p>As of December 31, 2025, GeneDx holds approximately $172 million in cash, cash equivalents, marketable securities, and restricted cash.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/preliminary2025resultspres.htm"></span></p><h3>Outlook / Guidance</h3><p>For 2026, GeneDx expects revenues between $540 and $555 million, with exome and genome revenue growth projected at 33% to 35%. The company also anticipates maintaining an adjusted gross margin of at least 70% and achieving positive adjusted net income.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/preliminary2025resultspres.htm"></span><span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/jpmorgan2026presentation.htm"></span></p>

GeneDx | 8-K: FY2025 Revenue Misses Estimate at USD 427 M